OBJECTIVES To predict multiple OLV attainment rates (per 1000) with the co-administration of fenofibric acid and low-dose statin (LDS) or moderate-dose statin (MDS) compared to equivalent dose statin monotherapy in Hispanic patients with mixed dyslipidemia. METHODS A dyslipidemia outcomes model was used to predict multiple OLV attainment rates (defined as achieving any of 3 of 4 targets: total-C, LDL-C, HDL-C, or TG) among a cohort of 1000 Hispanic patients with mixed dyslipidemia. The model simulates baseline lipid values to reflect natural co-variation using data from the National Health and Nutrition Examination Survey (1999-2004), simulates post-treatment improvements to reflect the lipid efficacy of each treatment comparator, and then compares post-treatment improvements to US guideline-based lipid targets (LDL-C <100 mg/dL, TG <150 mg/dL, total-C <200 mg/dL; HDL-C >40 mg/dL). Baseline lipid and lipid efficacy data for the Hispanic population were from a pooled analysis of three large, double-blind, Phase III, randomized controlled trials evaluating the efficacy and safety of fenofibric acid combined with LDS or MDS as compared to statin monotherapy at equivalent doses. RESULTS Compared to statin monotherapy, co-administration of fenofibric acid with LDS and MDS is predicted to increase multiple OLV attainment rates by 63% (546 to 890 per 1000) and 18% (630 to 745 per 1000), respectively. Fenofibric acid, when co-administered with a statin, is predicted to result in higher proportions of patients achieving individual TG and HDL-C target levels; while statin monotherapy treatment is predicted to result in higher proportions of patients achieving LDL-C targets. CONCLUSIONS These data suggest that co-administration of fenofibric acid and LDS or MDS may enable more patients to achieve multiple OLV compared to statin monotherapy in Hispanic patients with mixed dyslipidemia.